

Johnson & Johnson Statement on 2024 O'Brien Study

May 18, 2024 - Attributable to Erik Haas, Worldwide Vice President of Litigation, Johnson & Johnson

"This study does not change the overwhelming evidence that talcum powder does not cause ovarian cancer, and we remain confident these claims will be dismissed following Daubert review.

The study reinforces that, as the NIH has found for years, there is no evidence that genital talc powder products cause cancer. It is important to read this, and every study, in totality as it explicitly states that the 'results do not establish causality and do not implicate any specific cancer-inducing agent.' Further, in analyzing the actual data, the study concludes that there is an 'inverse or weakly positive associations between both types of intimate care products and all cancers of interest.' Only when speculative "assumptions" are layered over the actual data does the study infer a positive association. The Company stands by the safety of its talc products.

The Company remains focused on the consensual 'prepacked" reorganization plan introduced on May 1, which is in the best interests of the ovarian talc claimants. The Plan commits the Company to pay ovarian claimants a present value of approximately \$6.475 billion to be paid over 25 years, which is a far better recovery than the claimants stand to recover at trial. The Company has prevailed in approximately 95% of ovarian cases tried to date and in every case tried in the last six years. Most of these claimants have not recovered and will not recover anything at trial."